Ribonuclease Inhibitor (RNH1) Human shRNA Lentiviral Particle (Locus ID 6050)

CAT#: TL309781V

RNH1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Specifications

Product Data

• Locus ID: 6050
• Synonyms: RAI; RNH
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_002939, NM_203383, NM_203384, NM_203385, NM_203386, NM_203387, NM_203388, NM_203389, NM_203383.1, NM_203384.1, NM_203388.1, NM_203388.2, NM_002939.1, NM_002939.2, NM_002939.3, NM_203385.1, NM_203387.1, NM_203387.2, NM_203386.1, NM_203386.2, NM_203389.1, NM_203389.2, BC000677, BC000677.2, BC003506, BC003506.1, BC011500, BC011500.1, BC047730, BC047730.1, BC011186, BC014629, BC024037, BM019570, BM465975, BM562998, NM_203386.3, NM_203388.3, NM_203383.2, NM_002939.4, NM_203387.3, NM_203389.3
• UniProt ID: P13489
• Summary: Placental ribonuclease inhibitor (PRI) is a member of a family of proteinaceous cytoplasmic RNase inhibitors that occur in many tissues and bind to both intracellular and extracellular RNases (summarized by Lee et al., 1988 [PubMed 3219362]). In addition to control of intracellular RNases, the inhibitor may have a role in the regulation of angiogenin (MIM 105850). Ribonuclease inhibitor, of 50,000 Da, binds to ribonucleases and holds them in a latent form. Since neutral and alkaline ribonucleases probably play a critical role in the turnover of RNA in eukaryotic cells, RNH may be essential for control of mRNA turnover; the interaction of eukaryotic cells with ribonuclease may be reversible in vivo.[supplied by OMIM, Jul 2010]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).